Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHWAY: Parsaclisib in Primary Warm Autoimmune Hemolytic Anemia
2021-002844-66Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) and autoimmune haemolytic anaemia (AIHA) comparing Parsaclisib with Placebo (2 arms). Primary endpoint: Durable hemoglobin response. Started Sep 2021; status: completed.
02
Drugs
parsaclisib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2021-002844-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002844-66.